The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.
Adolescent
Adult
Aged
Biomarkers
/ blood
End Stage Liver Disease
/ blood
Female
Humans
Liver Transplantation
Male
Middle Aged
Models, Theoretical
Predictive Value of Tests
Risk Assessment
/ methods
Severity of Illness Index
Survival Rate
Waiting Lists
/ mortality
Young Adult
von Willebrand Factor
/ analysis
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
28
02
2019
accepted:
07
11
2019
pubmed:
28
11
2019
medline:
30
4
2021
entrez:
28
11
2019
Statut:
ppublish
Résumé
The Model for End-Stage Liver Disease (MELD) is used for clinical decision-making and organ allocation for orthotopic liver transplantation (OLT) and was previously upgraded through inclusion of serum sodium (Na) concentrations (MELD-Na). However, MELD-Na may underestimate complications arising from portal hypertension or infection. The von Willebrand factor (vWF) antigen (vWF-Ag) correlates with portal pressure and seems capable of predicting complications in patients with cirrhosis. Accordingly, this study aimed to evaluate vWF-Ag as an adjunct surrogate marker for risk stratification on the waiting list for OLT. Hence, WF-Ag at time of listing was assessed in patients listed for OLT. Clinical characteristics, MELD-Na, and mortality on the waiting list were recorded. Prediction of 3-month waiting-list survival was assessed by receiver operating characteristics and net reclassification improvement. Interestingly, patients dying within 3 months on the waiting list displayed elevated levels of vWF-Ag (P < 0.001). MELD-Na and vWF-Ag were comparable and independent in their predictive potential for 3-month mortality on the waiting list (area under the curve [AUC], vWF-Ag = 0.739; MELD-Na = 0.764). Importantly, a vWF-Ag cutoff at 413% identified patients at risk for death within 3 months of listing with a higher odds ratio (OR) than the previously published cutoff at a MELD-Na of 20 points (vWF-Ag, OR = 10.873, 95% confidence interval [CI], 3.160, 36.084; MELD-Na, OR = 7.594, 95% CI, 2.578, 22.372; P < 0.001, respectively). Ultimately, inclusion of vWF-Ag into the MELD-Na equation significantly improved prediction of 3-month waiting-list mortality (AUC, MELD-Na-vWF = 0.804). A single measurement of vWF-Ag at listing for OLT predicts early mortality. Combining vWF-Ag levels with MELD-Na improves risk stratification and may help to prioritize organ allocation to decrease waiting-list mortality.
Sections du résumé
BACKGROUND AND AIMS
The Model for End-Stage Liver Disease (MELD) is used for clinical decision-making and organ allocation for orthotopic liver transplantation (OLT) and was previously upgraded through inclusion of serum sodium (Na) concentrations (MELD-Na). However, MELD-Na may underestimate complications arising from portal hypertension or infection. The von Willebrand factor (vWF) antigen (vWF-Ag) correlates with portal pressure and seems capable of predicting complications in patients with cirrhosis. Accordingly, this study aimed to evaluate vWF-Ag as an adjunct surrogate marker for risk stratification on the waiting list for OLT.
APPROACH AND RESULTS
Hence, WF-Ag at time of listing was assessed in patients listed for OLT. Clinical characteristics, MELD-Na, and mortality on the waiting list were recorded. Prediction of 3-month waiting-list survival was assessed by receiver operating characteristics and net reclassification improvement. Interestingly, patients dying within 3 months on the waiting list displayed elevated levels of vWF-Ag (P < 0.001). MELD-Na and vWF-Ag were comparable and independent in their predictive potential for 3-month mortality on the waiting list (area under the curve [AUC], vWF-Ag = 0.739; MELD-Na = 0.764). Importantly, a vWF-Ag cutoff at 413% identified patients at risk for death within 3 months of listing with a higher odds ratio (OR) than the previously published cutoff at a MELD-Na of 20 points (vWF-Ag, OR = 10.873, 95% confidence interval [CI], 3.160, 36.084; MELD-Na, OR = 7.594, 95% CI, 2.578, 22.372; P < 0.001, respectively). Ultimately, inclusion of vWF-Ag into the MELD-Na equation significantly improved prediction of 3-month waiting-list mortality (AUC, MELD-Na-vWF = 0.804).
CONCLUSIONS
A single measurement of vWF-Ag at listing for OLT predicts early mortality. Combining vWF-Ag levels with MELD-Na improves risk stratification and may help to prioritize organ allocation to decrease waiting-list mortality.
Identifiants
pubmed: 31773739
doi: 10.1002/hep.31047
pmc: PMC7497135
doi:
Substances chimiques
Biomarkers
0
von Willebrand Factor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
584-594Informations de copyright
© 2019 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of American Association for the Study of Liver Diseases.
Références
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
Ann Hepatol. 2015 May-Jun;14(3):380-8
pubmed: 25864219
J Hepatol. 1999 Mar;30(3):451-5
pubmed: 10190728
Liver Transpl. 2008 Jun;14(6):837-44
pubmed: 18508377
Aliment Pharmacol Ther. 2014 Feb;39(3):331-8
pubmed: 24308724
Liver Int. 2016 Jul;36(7):1011-7
pubmed: 26814059
Hepatology. 2000 Apr;31(4):864-71
pubmed: 10733541
Hepatology. 2004 Oct;40(4):802-10
pubmed: 15382176
Toxicol Appl Pharmacol. 2017 Aug 1;328:54-59
pubmed: 28527913
Gut. 2011 Aug;60(8):1133-8
pubmed: 21427197
Liver Transpl. 2003 Jan;9(1):12-8
pubmed: 12514767
Liver Transpl. 2003 Feb;9(2):117-23
pubmed: 12548503
Hepatol Int. 2015 Jul;9(3):342-5
pubmed: 25820798
Alcohol Clin Exp Res. 2007 Jan;31(1 Suppl):S27-35
pubmed: 17331163
World J Hepatol. 2015 Apr 8;7(4):688-95
pubmed: 25866605
Immunol Res. 2017 Oct;65(5):1046-1058
pubmed: 28868583
Ann Surg. 2014 Jun;259(6):1186-94
pubmed: 24263317
Liver Transpl. 2017 Jan;23(1):11-18
pubmed: 27658200
Expert Rev Gastroenterol Hepatol. 2016 Jul;10(7):827-39
pubmed: 26838962
Transplantation. 2017 Jul;101(7):1542-1550
pubmed: 28060242
J Thromb Haemost. 2017 Jan;15(1):13-20
pubmed: 27778439
Liver Transpl. 2014 Nov;20 Suppl 2:S14-5
pubmed: 25269414
Biochem J. 1994 Sep 15;302 ( Pt 3):681-6
pubmed: 7524475
Expert Rev Gastroenterol Hepatol. 2015 Apr;9(4):431-45
pubmed: 25307897
Transpl Int. 2012 Sep;25(9):935-40
pubmed: 22775308
Transplantation. 2013 Jul 27;96(2):211-6
pubmed: 23765112
Hepatology. 2012 Jan;55(1):192-8
pubmed: 21898487
Am J Transplant. 2017 Sep;17(9):2410-2419
pubmed: 28226199
Eur J Clin Invest. 2009 Jan;39(1):65-71
pubmed: 19087131
Dig Dis Sci. 2017 Mar;62(3):768-776
pubmed: 28025746
Hepatology. 2006 Feb;43(2):345-51
pubmed: 16440361
J Thromb Haemost. 2012 Aug;10(8):1646-52
pubmed: 22642380
J Thromb Haemost. 2017 Jul;15(7):1285-1294
pubmed: 28671350
Transplant Proc. 2013 Sep;45(7):2676-9
pubmed: 24034022
J Hepatol. 2015 Apr;62(1 Suppl):S121-30
pubmed: 25920081
J Thromb Haemost. 2015 Sep;13(9):1699-708
pubmed: 26178390
Liver Int. 2006 Feb;26(1):55-61
pubmed: 16420510
N Engl J Med. 2012 Oct 18;367(16):1483-5
pubmed: 22992048
Liver Transpl. 2011 Feb;17(2):129-36
pubmed: 21280185
Hepatology. 1996 Jun;23(6):1377-83
pubmed: 8675154
Aliment Pharmacol Ther. 2018 Apr;47(7):980-988
pubmed: 29377193
Hepatology. 2012 Oct;56(4):1439-47
pubmed: 22532296
Gastroenterology. 2003 Jan;124(1):91-6
pubmed: 12512033
N Engl J Med. 2008 Sep 4;359(10):1018-26
pubmed: 18768945
Hepatology. 2018 Jan;67(1):273-281
pubmed: 28586179